Sullivan F M, Murray T S, Gaw N, Langan J J, Adams-Strump B J
Woodside Health Centre, Glasgow, U.K.
Eur Heart J. 1987 Nov;8 Suppl K:21-5. doi: 10.1093/eurheartj/8.suppl_k.21.
Nifedipine has been used in hypertension, mainly as a third-line drug for rapid blood pressure reduction, for over 10 years. More recently it has been shown to be effective and safe in reducing mild to moderate blood pressure when used alone in a slow release formulation. A placebo-controlled study investigating the efficacy and safety of nifedipine in comparison with cyclopenthiazide-potassium has now been carried out by 4 general practitioners in the Glasgow area. Ninety-four patients were entered into the study. After a 4-week placebo run-in phase, patients were randomly allocated to receive either slow-release nifedipine 20 mg b.d., or cyclopenthiazide 0.25 mg with 8.1 mmol potassium daily. The dose was doubled at week 8 for non-responders, and at week 12 the alternative drug was added if there was still no response. The patients were studied for up to 28 weeks. Nifedipine was found to have similar blood pressure lowering efficacy to cyclopenthiazide-potassium, but withdrawals from nifedipine due to side-effects at an early stage were more common.
硝苯地平用于治疗高血压已有10多年，主要作为快速降压的三线药物。最近有研究表明，单独使用缓释剂型的硝苯地平在降低轻至中度血压方面有效且安全。格拉斯哥地区的4名全科医生现已开展了一项安慰剂对照研究，比较硝苯地平和环戊噻嗪 - 钾的疗效和安全性。94名患者参与了该研究。在为期4周的安慰剂导入期后，患者被随机分配接受每日两次、每次20毫克的缓释硝苯地平，或每日服用0.25毫克环戊噻嗪和8.1毫摩尔钾。对于无反应者，在第8周将剂量加倍，若至第12周仍无反应，则加用另一种药物。对患者进行了长达28周的研究。结果发现，硝苯地平降低血压的疗效与环戊噻嗪 - 钾相似，但早期因副作用而停用硝苯地平的情况更为常见。
